liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
The role of immunomodulation therapy in autoimmune diabetes
Linköping University, Department of Clinical and Experimental Medicine, Pediatrics. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Center of Paediatrics and Gynaecology and Obstetrics, Department of Paediatrics in Linköping. (Immune Intervention Study Group Linköping)
2009 (English)In: Journal of Diabetes Science and Technology, ISSN 1932-2968, E-ISSN 1932-2968, Vol. 3, no 2, 320-330 p.Article, review/survey (Refereed) Published
Abstract [en]

Type 1 diabetes (T1DM) is characterized by loss of virtually all endogenous insulin secretion. If residual insulin secretion is preserved, this will lead to improved metabolic balance, less acute and late complications, improved quality of life, and, in case of pronounced improvement of residual insulin secretion, complete remission and even cure of the disease. Immune suppression or immune modulation have been demonstrated as a proof of principle to stop/decrease the destructive process and thereby preserve beta-cell function. Several methods to save residual beta-cell function have been tried for more than three decades with little or no evidence of efficacy. Positive effects have been seen mainly in adult patients but have been minimal or absent in children with diabetes. Furthermore, the safety of these immune interventions and/or their benefit to risk relationships have not been found to justify clinical use. More specific immune modulation with anti-CD3 monoclonal antibodies has resulted in more encouraging postponement of C-peptide decline, but with frequent and serious adverse effects. Still more promising are the autoantigen therapies, of which glutamic acid decarboxylase (GAD) vaccination has shown significant preservation of residual insulin secretion in 10-18-year-old type 1 diabetes patients with recent onset. Efficacy was most impressive in the subgroup of patients with diabetes of short duration (less than3 months). The treatment was simple, well tolerated, and showed no treatment-related adverse events. If these results can be confirmed, there is a realistic hope that GAD vaccination, perhaps in combination with vaccinations with other autoantigens and/or other therapies, will result in remission for some patients. The prospects of cure and prevention of T1DM will become less remote.

Place, publisher, year, edition, pages
Sage Publications, 2009. Vol. 3, no 2, 320-330 p.
Keyword [en]
autoantigen treatment, C-peptide, glutamic acid decarboxylase vaccination, immune intervention, immunomodulation, type 1 diabetes
National Category
Endocrinology and Diabetes
URN: urn:nbn:se:liu:diva-59130DOI: 10.1177/193229680900300213OAI: diva2:352107
Available from: 2010-09-17 Created: 2010-09-09 Last updated: 2015-11-19Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Ludvigsson, Johnny
By organisation
PediatricsFaculty of Health SciencesDepartment of Paediatrics in Linköping
In the same journal
Journal of Diabetes Science and Technology
Endocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 19 hits
ReferencesLink to record
Permanent link

Direct link